Discover the Power of Early Autism Diagnosis with EarliPoint™
Your Child Deserves the Best Start
As a parent, you watch your child grow and notice every smile, laugh, or new word. Sometimes, though, something might feel a little different. Have you noticed things like limited eye contact, delayed speech, or lack of interest in social play? About 1 in 6 children have a developmental disability.1 If you are worried about your child’s development, trust your instincts. Early diagnosis and intervention can make a big difference—and EarliPoint™ is here to help.
EarliPoint™ by EarliTec Diagnostics is an FDA-cleared tool that helps diagnose Autism Spectrum Disorder (ASD) in children as young as 16 months. Using eye-tracking technology, EarliPoint measures how your child views real world social interactions, giving you and your healthcare provider a clear picture of their development. With an early diagnosis, you can start treatment at the right time—giving your child the best chance to succeed.
What Makes EarliPoint Different?
Most autism diagnosis methods rely on observations and parent interviews, which can mean a long wait for answers—sometimes until a child is 4 or 5 years old.2-3 That’s valuable brain development time lost.4 EarliPoint changes this. It is an objective, FDA-cleared tool that helps with early diagnosis. EarliPoint can also objectively track your child’s progress, comparing it to their own initial baseline.
The EarliPoint System device is indicated as a tool to aid qualified clinicians in the diagnosis and assessment of Autism Spectrum Disorder (ASD) in children ages 16 months through 30 months, who are at risk based on concerns identified by a parent, caregiver, or healthcare provider. The EarliPoint System is a prescription medical device.
Taking Charge of Your Child’s Future
If your child is under 3 years old, you might be focused on their milestones—wondering if they are developing as expected. You are not alone. It can feel overwhelming for first time parents! By using advanced eye-tracking technology, FDA-cleared EarliPoint helps to detect autism, objectively, in 16–30-month-old children, so you do not have to rely only on subjective observations or questionnaires. EarliPoint™ gives you objective results that can guide the next steps for your child’s care. With EarliPoint, you will get an accurate, data-driven assessment that provides a clear path forward—helping you make the best decisions for your child without feeling uncertain.
With EarliPoint, you get:
Early and Accurate Assessment: EarliPoint tracks where a child looks every moment, in ways we can’t see with just our eyes. For the child, it’s as easy as watching a short video of toddlers playing. The device checks where the child focuses 120 times per second. It then compares this data to thousands of measurements in a trusted database, helping to identify signs of autism. This gives parents, caregivers, and doctors quick, clear, and accurate information about possible developmental concerns.
Progress Tracking: EarliPoint does not stop at diagnosis. It can also track your child’s monthly progress over time, comparing each new assessment to their initial baseline. This allows you to see how your child is growing and adjusting to their care to help them succeed.
- Clear, Actionable Insights: Instead of feeling lost in a maze of information, EarliPoint provides you with a personalized profile of your child’s strengths and challenges. This information helps you work with healthcare providers to create a plan that fits your child’s unique needs.
Why Early Diagnosis with EarliPoint Matters
Autism affects 1 in 31 children,6 but many kids do not get a diagnosis until they are 4 or 5 years old; valuable time lost when early help could make a big difference.5 The EarliPoint™ system can aid in a diagnosis as early as 16 months. The EarliPoint report provides parents with valuable insights such as social disability, verbal learning, and cognitive nonverbal learning comparing your child to other typically developing children. Early diagnosis means you can start the right therapies sooner, helping your child build skills in communication, social interaction, and daily activities.
What Parents Are Saying
Parents say EarliPoint gave them peace of mind and confidence to move forward. Instead of feeling stuck or overwhelmed, they were able to take steps that made a difference for their child. Early support means more opportunities for growth, better chances for school readiness, and improved outcomes.
Trust Your Instincts—Get the Answers Your Child Deserves
If you have noticed things like limited eye contact, delayed speech, or lack of interest in social play, do not wait. The earlier your child gets the support they need, the brighter their future can be. EarliPoint™ is here to provide clear, objective answers you can trust.
Learn more about how EarliPoint™ can help you take the first step toward supporting your child’s potential. Contact us today to find an EarliPoint™ testing center near you.
EarliPoint™—Empowering Parents, Changing Futures.
References
1. Abercrombie J, Wiggins L, Green KK. CDC’s “Learn the Signs. Act Early.” Developmental Milestone Resources to Improve Early Identification of Children with Developmental Delays, Disorders, and Disabilities. Zero Three. 2022 Sep;43(1):5-12. PMID: 37207257; PMCID: PMC10193264. https://pmc.ncbi.nlm.nih.gov/articles/PMC10193264/
2. Christensen DL, Baio J, Van Naarden Braun K, et al; Centers for Disease Control and Prevention. Prevalence and characteristics of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2012. MMWR Surveill Summ. 2016;65(3):1-23. doi:10.15585/mmwr.ss6503a1. https://pmc.ncbi.nlm.nih.gov/articles/PMC6237390/
3. Shaw KA, McArthur D, Hughes MM, et al. Progress and disparities in early identification of autism spectrum disorder: Autism and Developmental Disabilities Monitoring Network, 2002-2016. J Am Acad Child Adolesc Psychiatry. 2022;61(7):905-914. doi:10.1016/j.jaac.2021.11.019. https://pmc.ncbi.nlm.nih.gov/articles/PMC9353949/
4. Rapoport J, Gogtay N; Brain Neuroplasticity in Healthy, Hyperactive and Psychotic Children: Insights from Neuroimaging; Neuropsychopharmacology Reviews (2008) 33, 181–197; doi:10.1038/sj.npp.1301553; published online 12 September 2007. https://www.nature.com/articles/1301553
5. Jones W, Klaiman C, et al. Development and Replication of Objective Measurements of Social Visual Engagement to Aid in Early Diagnosis and Assessment of Autism; JAMA Network Open. 2023;6(9): e2330145. doi:10.1001/jamanetworkopen.2023.30145